-
Fosmanogepix is an
experimental antifungal drug
being developed by
Amplyx Pharmaceuticals (now
currently by
Pfizer and Basilea) It is
being investigated...
-
Cornely OA,
Krause R, et al. (9
October 2021). "The
Antifungal Pipeline:
Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin". Drugs. 81 (15):...
- of
fungal proteins.
Manogepix is the
active metabolite of the
prodrug fosmanogepix.
Pfaller MA, Hata K,
Jones RN,
Messer SA, Moet GJ,
Castanheira M (October...
-
Pfizer acquired Amplyx Pharmaceuticals and its anti-fungal
compound fosmanogepix (APX001). In August, the
company announced it
would acquire Trillium...
-
Cornely OA,
Krause R, et al. (October 2021). "The
Antifungal Pipeline:
Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin". Drugs. 81 (15):...
-
responsible for the
preclinical development of the
novel antifungal fosmanogepix, a first-in-class broad-spectrum
antifungal prodrug that is currently...
- however,
disease progressed on this regimen, and
patients were
trialed on
fosmanogepix through a comp****ionate use authorization. F.
solani has been investigated...
- anti-infectives. In 2023,
Basilea acquired the
rights to the
antifungal drug
Fosmanogepix from Pfizer. By the end of 2023,
Isavuconazole was
commercialised in...
-
somewhat effective in
treating S. prolificans infections.
Another drug,
fosmanogepix,
another fungal enzyme inhibitor,
showed in
vitro efficacy as treatment...
